Paul Mampilly is very focused on business and investments. Paul was born in India, and later in his early age, he moved to America. He started his career at Wall Street way back in 1991 at Bankers Trust as an assistant portfolio manager. With determination and hard work, Paul advanced quickly andacquired prominent positions at ING and Deutsche Bank. His progress was evident, and in 2006, Kinetics Asset Management employed him to manage Hegde funds. Also, Paul has invested in many companies which have given him high returns.
Paul Mampilly has achieved very many things as an investor. He invested in drug manufacturing company which specialized in developing drugs for muscular dystrophy. He then sold all his shares at Sarepta Therapeutics and got over two thousand percent gains. Later in 2008, Paul invested in Netflix which also gave him significant profit. His investment helps him generate more revenue within a short time through the stock market. He has also invested in Whole food business, Cemex, and Grifols.
While he was working at Kinetics Asset Management, Paul helped the company the company growing their assets at 26% annually. This significant development was as a result of creative and proper management skills that Paul used to manage the business. Paul was invited to participate in an investment competition sponsored by Templeton Foundation. In the contest, Mampilly started with$50 million, and after a year he had grown the investment to over $88 million. This made him win the competition.
At 42, Paul Mampilly retired and started Profits Unlimited which is a publishing company that finds good stocks in the stock exchange market. This firm aims to help many people to invest their money wisely in the stock exchange market. He provides great and valuable tips that are very beneficial to investors. Also, Paul has been invited to different Tv shows where he shares his knowledge and advice with people on proper investment strategies.
Also, Paul Mampilly offers advice related to anticipation of growth in food delivery systems, precision medicine, and electric vehicles. Mampilly believes soon significant development is anticipated in these industries and this should be taken as an investment opportunity. This advice should be taken into consideration as from his achievements; Paul Mampilly can be wrong.